A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

NCT04260802 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

73

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Cancer
Neoplasms
Metastatic Cancer
Triple Negative Breast Cancer
Gastric Cancer
Cervical Cancer
Ovarian Cancer
Hepatocellular Carcinoma
Squamous Cell Carcinoma of Head and Neck
Urothelial Carcinoma
Urothelial Neoplasm
Non Small Cell Lung Cancer
Renal Cell Carcinoma
Locally Advanced Solid Tumor
Locally Advanced Malignant Neoplasm
Squamous Cell Carcinoma
Sarcoma
Merkel Cell Carcinoma
Bladder Cancer

Interventions

DRUG: OC-001
DRUG: Drug: OC-001 in Combination with Avelumab

Sponsor

Ocellaris Pharma, Inc.